PIA
AEGR

Piedmont Investment Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Piedmont Investment Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-145
Closed -$1.97K – 433
2015
Q3 		$1.97K Buy
145
+44
+44% +$783 ﹤0.01% 337
2015
Q2 		$1.92K Buy
+101
New +$2.19K ﹤0.01% 348

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Piedmont Investment Advisors's AEGR Position: Q4 2015 in Review

Piedmont Investment Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 145 shares — an estimated $1.97K sold.

Piedmont Investment Advisors first reported a position in AEGR in Q2 2015 and held it in 2 quarters. The position peaked at $1.97K in Q3 2015. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Piedmont Investment Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Piedmont Investment Advisors sold 145 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $1.97K.
  • Piedmont Investment Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Piedmont Investment Advisors's Aegerion Pharmaceuticals position peaked at $1.97K in Q3 2015.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Piedmont Investment Advisors's 13F filing for Q4 2015, filed 21 Jan 2016.